Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Atezolizumab (Primary)
- Indications Smoldering multiple myeloma
- Focus Pharmacodynamics
- 28 Feb 2020 Status changed from suspended to discontinued.
- 05 Jan 2018 Status changed from recruiting to suspended.
- 01 Dec 2016 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.